GLP-1 receptor agonists
2 articles · search the full text for this term
-
GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and Obesity
Abstract: For the treatment of obesity and type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a revolutionary class of pharmaceutical drugs. These drugs were first created as glucose-lowering treatments, but they have now shown other advantages, such as notable weight loss, better cardiovascular results, and general metabolic control. The objective of this narrative review is to assess the pharmacological mechanisms, clinical efficacy, safety profile, and therapeutic …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 1, 2026 · pp. 69–75 Read article
-
Assessment of Finerenone Safety and Efficacy in Individuals with Type 2 Diabetes and Chronic Kidney Disease
Abstract: Background: In this work, we provide strong evidence for the safety and efficacy of finerenone in people with type 2 diabetes and chronic kidney disease. Our goal is to improve patients' quality of life and general well-being through our research. Aim: Finerenone exhibited a significant decrease in the likelihood of renal and cardiovascular (CV) events in individuals with both type 2 diabetes and chronic kidney disease. This exploratory subgroup analysis …
Published in International Journal of Antibiotics · Vol. 1, Issue 2, 2024 · pp. 06–09 Read article